Portal de Periódicos da CAPES

HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population

2013; Elsevier BV; Volume: 71; Issue: 2 Linguagem: Inglês

10.1016/j.jdermsci.2013.04.013

1873-569X

Hiroyuki Niihara, Sakae Kaneko, Takahumi Ito, Takashi Sugamori, Nobuyuki Takahashi, Kunie Kohno, Eishin Morita,

Urticaria and Related Conditions

Allopurinol, an inhibitor of xanthine oxidase, is widely used for the treatment of hyperuricemia associated with chronic gout, acute uric acid nephropathy, recurrent uric acid stone formation, certain enzyme/blood disorders, and cancer chemotherapy. It has been shown that severe cutaneous adverse drug reactions (ADRs) caused by allopurinol were strongly associated with HLA-B*58:01 in a Han Chinese sample population [1]. Odds ratio (OR) for the association of HLA-B*58:01 with allopurinol-induced severe cutaneous ADR in this population was 580.3 and 95% CI was 34.4–9780.9.